Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators. Ravina B, et al. Among authors: kieburtz k. Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690. Mov Disord. 2009. PMID: 19691116
Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips J, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud TM, Toga AW, Tanner CM, Kieburtz KD, Mollenhauer B, Galasko D, Hutten S, Weintraub D, Siderowf AD, Marek K, Poston KL, Shaw LM; Parkinson's Progression Markers Initiative. Cousins KAQ, et al. Among authors: kieburtz kd. Neurology. 2024 Feb;102(4):e208033. doi: 10.1212/WNL.0000000000208033. Epub 2024 Feb 2. Neurology. 2024. PMID: 38306599
Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
Dorsey ER, Kinel D, Pawlik ME, Zafar M, Lettenberger SE, Coffey M, Auinger P, Hylton KL, Shaw CW, Adams JL, Barbano R, Braun MK, Schwarz HB, Lawrence BP, Kieburtz K, Tanner CM, de Miranda BR, Goldman SM. Dorsey ER, et al. Among authors: kieburtz k. Mov Disord. 2024 Mar;39(3):606-613. doi: 10.1002/mds.29723. Epub 2024 Feb 23. Mov Disord. 2024. PMID: 38389433
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials initiative.
Wyse RK, Isaacs T, Barker RA, Cookson MR, Dawson TM, Devos D, Dexter DT, Duffen J, Federoff H, Fiske B, Foltynie T, Fox S, Greenamyre JT, Kieburtz K, Kordower JH, Krainc D, Matthews H, Moore DJ, Mursaleen L, Schwarzschild MA, Stott SRW, Sulzer D, Svenningsson P, Tanner CM, Carroll C, Simon DK, Brundin P. Wyse RK, et al. Among authors: kieburtz k. J Parkinsons Dis. 2024 Apr 5. doi: 10.3233/JPD-230363. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38578902 Review.
301 results